Scientific Evidence and Autoimmune Diseases: What Does Regenerative Medicine Really Say?
Last medical review: February 2026 · Read time: 8 min
Important notice: This article analyzes clinical studies and biological mechanisms. Cell therapy is an adjuvant treatment focused on immunomodulation and does not substitute, initially, conventional pharmacological treatment without medical supervision.
For decades, the approach to autoimmune diseases has been based on a "war" strategy: suppressing the immune system with potent drugs (corticosteroids, methotrexate, biologics) to stop the attack on the body's own tissues. While this strategy saves lives, it often carries severe side effects and does not repair the damage already caused.
In this context, evidence-based regenerative medicine has introduced a paradigm shift: moving from immunosuppression to immunomodulation. But, beyond testimonials, what is the real scientific backing behind the use of Mesenchymal Stem Cells (MSCs) in complex pathologies?
The Biological Mechanism: How Do Cells "Talk"?
Classic outreach texts usually say that stem cells "repair tissues." However, current science tells us that their main function in autoimmune processes is much more sophisticated. They do not act just as bricks, but as "conductors of an orchestra."
Studies demonstrate that MSCs exert their therapeutic effect through three key mechanisms:
- Paracrine Immunomodulation: Cells release vesicles (exosomes) and cytokines that "re-educate" regulatory T-Cells, instructing the immune system to cease aggression against the body itself.
- Homing (Migration): They have the ability to detect inflammation signals and migrate specifically towards damaged tissues, whether in the joints or internal organs.
- Anti-fibrotic Effect: They help prevent chronic inflammation from turning functional tissue into scar tissue (fibrosis), vital in conditions like Lupus or Systemic Sclerosis.
Clinical Evidence by Pathology
Below, we break down current evidence based on recent clinical trials and meta-analyses, separating hope from measurable clinical results.
1. Rheumatoid Arthritis (RA)
In RA, the immune system destroys cartilage and bone. Phase I/II studies have shown that MSC infusion can significantly reduce levels of inflammatory markers (such as CRP and ESR) in patients who do not respond to traditional biological drugs. The goal is not only to relieve pain but to stop joint erosion.
2. Systemic Lupus Erythematosus (SLE)
This is perhaps one of the most promising areas. Research published in journals like Stem Cell Research & Therapy has documented clinical remission rates and reduction in disease activity (SLEDAI index), especially in cases of lupus nephritis (kidney damage), helping to preserve the function of vital organs and tissues.
3. Multiple Sclerosis (MS)
While it is a complex neurodegenerative condition, the ability of stem cells to modulate inflammation in the central nervous system offers a pathway to stabilize progression. The focus centers on neuroprotection and improving the patient's quality of life in the face of chronic fatigue.
The Critical Variable: Safety and Laboratory Quality
Here lies the difference between a successful treatment and a health risk. A scientific study is conducted under controlled laboratory conditions. To replicate those results in a patient, the medical center must meet rigorous standards.
At Regencord, we do not improvise. We apply ISO 9001, ISO 13022, and ISO 14644 regulations. This guarantees that the cells you receive:
- Have been cultured in sterile clean rooms (free of bacteria and viruses).
- Maintain a viability greater than 90% at the time of application.
- Have complete genetic traceability.
"Garage medicine" without ISO certification is the greatest enemy of scientific evidence.
Frequently Asked Questions about Current Evidence
Does this treatment replace my current medicine?
Not immediately. Evidence suggests a combined approach. The goal is to achieve clinical stability that allows, over time and under medical criteria, to progressively reduce immunosuppressant doses to minimize their toxic effects.
How long do results last?
The answer is individual and depends on the chronicity of the disease. Studies report remission periods that can last from months to years. In autoimmune diseases, booster doses are often recommended to maintain immunological modulation.
What do studies say about side effects?
Mesenchymal Stem Cells are "immunoprivileged," meaning they have an extremely low risk of rejection. Meta-analyses confirm a high safety profile, with the most common adverse effects being mild and transient (such as mild fever post-infusion).
Selected References
- Wang, D., et al. (2014). Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Research & Therapy.
- Llufriu, S., et al. (2014). Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLOS ONE.
- Colombian Regulation: Resolution 8430 of 1993 (Health Research) and ISO Standards applicable to biotechnology.
Medical Evaluation Based on Science
If you are looking for options beyond conventional management, it is vital to analyze your case with scientific rigor. At Regencord, we review your medical history to determine if cellular immunomodulation is a viable strategy for your diagnosis.
We invite you to schedule a specialized medical assessment to discuss the real possibilities of your treatment.
